Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04459988 · ClinicalTrials.gov registry record
Mechanistic Study of Ocrevus
A clinical trial, sponsored by University of Michigan.
- Completed
- Registry status
- 35
- Enrollment target
NCT04459988 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 35 participants.
The verdict
NCT04459988 has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the immune cell and other factor changes with Ocrevus in Multiple Sclerosis (MS) patients. Researchers will recruit 35 participants for this study. Patients will be enrolled from the Multiple Sclerosis Center at the University of Michigan Health System in Ann Arbor. The goal of the study is to understand the role of regulatory B cell, T cell and other factors in mediating the therapeutic effects of Ocrevus.
Interventions
- DRUG Ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-07-01 |
| Est. Completion | 2022-10-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04459988
The ClinicalTrials.gov registry entry for NCT04459988 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ocrelizumab is the first listed.
NCT04459988 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04459988 about?
NCT04459988 is a clinical study titled "Mechanistic Study of Ocrevus". The purpose of this study is to investigate the immune cell and other factor changes with Ocrevus in Multiple Sclerosis (MS) patients. Researchers will recruit 35 participants for this study. Patients will be enrolled from the Multiple Sclerosis Center at the University of Michigan Health System in ...
What is the current status of trial NCT04459988?
This trial is currently completed. The enrollment target is 35 participants. The study started on 2020-07-01. Estimated completion is 2022-10-25.
What interventions are being tested in trial NCT04459988?
The interventions under investigation include: Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT04459988?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.